USPH Enterprise Value Over E B I T D A from 2010 to 2024

USPH Stock  USD 96.94  2.88  3.06%   
US Physicalrapy's Enterprise Value Over EBITDA is increasing with slightly volatile movements from year to year. Enterprise Value Over EBITDA is estimated to finish at 20.15 this year. For the period between 2010 and 2024, US Physicalrapy, Enterprise Value Over EBITDA quarterly trend regression had median of  15.57 and r-value of  0.65. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
19.18993627
Current Value
20.15
Quarterly Volatility
16.40053637
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check US Physicalrapy financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among US Physicalrapy's main balance sheet or income statement drivers, such as Interest Expense of 9.8 M, Total Revenue of 635 M or Gross Profit of 117.6 M, as well as many indicators such as Price To Sales Ratio of 2.99, Dividend Yield of 0.0194 or PTB Ratio of 4.71. USPH financial statements analysis is a perfect complement when working with US Physicalrapy Valuation or Volatility modules.
  
Check out the analysis of US Physicalrapy Correlation against competitors.
For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.

Latest US Physicalrapy's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of US Physicalrapy over the last few years. It is US Physicalrapy's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in US Physicalrapy's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

USPH Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean10.77
Coefficient Of Variation152.29
Mean Deviation8.86
Median15.57
Standard Deviation16.40
Sample Variance268.98
Range66.878
R-Value0.65
Mean Square Error167.21
R-Squared0.42
Significance0.01
Slope2.38
Total Sum of Squares3,766

USPH Enterprise Value Over E B I T D A History

2024 20.15
2023 19.19
2022 17.29
2021 16.64
2020 20.87
2019 18.93
2018 18.23

About US Physicalrapy Financial Statements

Investors use fundamental indicators, such as US Physicalrapy's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although US Physicalrapy's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 19.19  20.15 

Currently Active Assets on Macroaxis

When determining whether US Physicalrapy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of US Physicalrapy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Us Physicalrapy Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Us Physicalrapy Stock:
Check out the analysis of US Physicalrapy Correlation against competitors.
For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.24)
Dividend Share
1.75
Earnings Share
0.88
Revenue Per Share
42.489
Quarterly Revenue Growth
0.12
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, US Physicalrapy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.